- Home
- MGRM vs ABOS Comparison
MGRM vs ABOS Comparison
Compare MGRM & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRM
- ABOS
- Stock Information
- Founded
- MGRM 2016
- ABOS 1996
- Country
- MGRM United States
- ABOS United States
- Employees
- MGRM N/A
- ABOS N/A
- Industry
- MGRM Medical/Dental Instruments
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- MGRM Health Care
- ABOS Health Care
- Exchange
- MGRM Nasdaq
- ABOS Nasdaq
- Market Cap
- MGRM 89.6M
- ABOS 99.1M
- IPO Year
- MGRM N/A
- ABOS 2021
- Fundamental
- Price
- MGRM $2.57
- ABOS $1.65
- Analyst Decision
- MGRM Strong Buy
- ABOS Strong Buy
- Analyst Count
- MGRM 1
- ABOS 3
- Target Price
- MGRM $4.00
- ABOS $9.33
- AVG Volume (30 Days)
- MGRM 63.8K
- ABOS 412.7K
- Earning Date
- MGRM 03-14-2025
- ABOS 11-12-2024
- Dividend Yield
- MGRM N/A
- ABOS N/A
- EPS Growth
- MGRM N/A
- ABOS N/A
- EPS
- MGRM N/A
- ABOS N/A
- Revenue
- MGRM $364,999.00
- ABOS N/A
- Revenue This Year
- MGRM N/A
- ABOS N/A
- Revenue Next Year
- MGRM N/A
- ABOS N/A
- P/E Ratio
- MGRM N/A
- ABOS N/A
- Revenue Growth
- MGRM N/A
- ABOS N/A
- 52 Week Low
- MGRM $1.53
- ABOS $1.53
- 52 Week High
- MGRM $4.90
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- MGRM 54.65
- ABOS 39.18
- Support Level
- MGRM $2.35
- ABOS $1.54
- Resistance Level
- MGRM $2.80
- ABOS $1.75
- Average True Range (ATR)
- MGRM 0.20
- ABOS 0.13
- MACD
- MGRM -0.01
- ABOS 0.01
- Stochastic Oscillator
- MGRM 54.00
- ABOS 28.57
About MGRM Monogram Orthopaedics Inc.
Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.